ClinicalTrials.gg
RecruitingNCT05804331ANZ UGIUpdated Mar 27, 2025

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

An observational study in Cancer of Stomach, Oesophageal Cancer and Gastric Cancer, sponsored by Western Sydney Local Health District. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Western Sydney Local Health District · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Stomach Neoplasms with a site in Australia — 29 open to participants now, 51 under way, 8 of them phase 3. Stomach Neoplasms · Australia.

Started
2023
with 8 others
Observational
2 of 110
1 open now
Primary completion
2028-03
later than 30 of 50 live
Registered
73rd of 110
by date

Among the 110 studies in Stomach Neoplasms with a site in Australia, this one is one of 9 that started in 2023, is one of 2 observational ones, reaches primary completion later than 30 of the 50 other live ones, and was the 73rd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

29 of the 110 studies in Stomach Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Stomach Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

Read the detailed description

To collect prospective observational data on patients undergoing ESD, EFTR or STER for UGI neoplastic lesions

  • Lesion characteristics including histology
  • Procedural outcomes
  • Safety Outcomes
  • Efficacy outcomes
03

Conditions studied

  • Cancer of Stomach
  • Oesophageal Cancer
  • Gastric Cancer
  • Gastric Adenocarcinoma
  • GI Cancer
  • GIST
  • Neuroendocrine Tumors
  • Gastric Neoplasm
  • Esophageal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred to tertiary centre for endoscopic resection of gastrointestinal neoplasm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • UGI neoplastic lesions > 10mm

    • Lesions for ESD limited to the mucosal and/or submucosal layer OR
    • Lesions for EFTR limited to the muscularis propria layer OR
    • Lesions for STER limited to the submucosal and/or muscularis propria layer
  • Aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Age less than 18
  • Unable to give
  • Pregnant or lactating patients
  • Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Patient with Gastrointestinal neoplasm

    Pt referred for resection of gastrointestinal neoplasm. Observational data collected from endoscopic submucosal dissection (ESD), submucosal-tunnelling endoscopic resection (STER) or endoscopic full-thickness resection (EFTR) of gastrointestinal neoplasm

06

What researchers measure

Primary outcomes

  1. Effectiveness of endoscopic resection of UGI neoplastic lesions: completeness of resection

    Determined based on clear margins in histology review

    Time frame: 2 weeks

  2. Safety: intra and post procedural; bleeding; perforation; anaesthetic

    Intraprocedural bleeding, clinically significant post-polypectomy bleeding, deep mural injury, post polypectomy coagulation syndrome

    Time frame: 30 day

  3. Long term outcomes: recurrent and residual disease

    Determined at subsequent procedures

    Time frame: 3 years

Secondary outcomes

  1. Endoscopic sessions, procedure time (in minutes) and overall time (in weeks) needed to achieve the primary objectives

    Determined after follow up procedure to confirm no recurrence

    Time frame: 6 months

  2. Need for more than one endoscopic therapy

    Determined after follow up procedures

    Time frame: 3 years

  3. Need for surgery

    Determined after follow up procedures, histological review

    Time frame: 2 months

  4. Post ESD, EFTR, STER defect features

    Determined after complete resection

    Time frame: 1 day

  5. Patient interviews/questionnaires

    Determined after follow up procedures

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 60 months is close to that.

Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2023
First posted
Apr 7, 2023
StartActual
Mar 14, 2023
Primary completionEst.
Mar 14, 2028
CompletionEst.
Sep 14, 2028
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05804331
Lead sponsor
Western Sydney Local Health District
Responsible party
Professor Michael Bourke (Director of Endoscopy, Western Sydney Local Health District) — Principal investigator
First posted
Apr 7, 2023
Start date
Mar 14, 2023
Primary completion
Mar 14, 2028 (estimated)
Completion
Sep 14, 2028 (estimated)
Last update
Mar 27, 2025

Study contacts

Michael Bourke
Contact
michael@citywestgastro.com.au
02 8890 5555
Michael Bourke
principal investigator · WSLHD

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion